The University of Missouri takes a giant leap in cancer care with the launch of its first on-campus radiopharmaceutical clinical trial. This groundbreaking initiative, a collaboration between the School of Medicine and MU Health Care, showcases the university's comprehensive research capabilities, from development to human trials. Working with ABK Biomedical, cancer researchers at the School of Medicine have enrolled their first patient in a clinical trial at MU Health Care's Ellis Fischel Cancer Center, using Eye90 microspheres and treatment commenced on February 9th. This marks a significant milestone as Mizzou expands its capacity to conduct radiopharmaceutical clinical trials, in collaboration with the NextGen Precision Health initiative. President Mun Choi emphasizes the power of campus research, highlighting the nation's largest university research reactor and unmatched research facilities in veterinary medicine, the School of Medicine, and NextGen Precision Health, enabling faculty and researchers to partner with industry for groundbreaking treatments and faster patient access. Eye90 microspheres, designed for precise visualization during delivery, are engineered to target liver tumors with localized radiation therapy, enhancing treatment efficacy while minimizing exposure to healthy tissue. The University of Missouri Research Reactor (MURR) is the sole domestic source of Y-90, the radioisotope embedded in the microspheres, and creates them for ABK Biomedical. Ryan Davis, associate professor of clinical radiology, notes the significance of this trial for Ellis Fischel, providing early access to therapies and continuing leadership in translational research. The collaboration with ABK Biomedical is advancing cancer treatment in Columbia and beyond, with Matt Sanford praising the support for groundbreaking nuclear medicine advancements. Mizzou's pioneering role in glass microsphere development for Y-90 therapy since the 1980s is notable, with the TheraSphere receiving full FDA approval in 2021 and MURR as the sole U.S. producer. The partnership with ABK Biomedical for on-site irradiation and processing of microspheres has established a reliable capability for preclinical and clinical trials. Mizzou researchers, including Jeffrey Bryan, conducted effectiveness and safety studies for Eye90 microspheres, laying the groundwork for the human clinical trial. Bryan's initial small animal model studies and subsequent clinical trial in dogs with liver tumors demonstrated the microspheres' efficacy and safety. The Mizzou clinical trial is part of a broader effort to evaluate Eye90 microspheres in patients with unresectable liver tumors, with a single administration followed by a year-long monitoring period to assess outcomes. ABK Biomedical's previous studies, including the first patient treated at Auckland Hospital in New Zealand, aim to gather comprehensive data for regulatory approvals and clinical adoption. Mizzou and Ellis Fischel remain committed to pioneering advanced treatments and improving patient care through cutting-edge research and collaboration.
